Clinical efficacy and safety of Danshu Capsule in treatment of chronic cholecystitis and gallstones

Xuelian PENG; Xiaoqing XU; Qin CAO

doi:10.3969/j.issn.1001-5256.2022.09.025

Volume 38 Issue 9

Sep. 2022

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(9): 2084-2090

PDF( 1981 KB)

Clinical efficacy and safety of Danshu Capsule in treatment of chronic cholecystitis and gallstones

DOI: 10.3969/j.issn.1001-5256.2022.09.025

Department of Gastroenterology, Putuo District Central Hospital, Shanghai 200062, China

Research funding:

National Natural Science Foundation of China (81603468)

More Information

Corresponding author: CAO Qin, taihefuxiaokui@163.com(ORCID: 0000-0003-1748-3451)
Received Date: 2021-06-15
Accepted Date: 2021-07-21
Published Date: 2022-09-20

Abstract

Abstract

Objective To investigate the clinical efficacy and safety of Danshu Capsule in the treatment of chronic cholecystitis and gallstones through a large-sample, multicenter, open-label real-world research. Methods A total of 9579 patients with chronic cholecystitis and/or gallstones who were treated in 329 hospitals of China from January 2017 to December 2019 were enrolled and divided into gallstones group with 1148 patients, chronic cholecystitis group with 5360 patients, and chronic cholecystitis+gallstones group with 3071 patients.All patients were treated with oral administration of Danshu Capsule at a frequency of 1-2 capsules/time, three times a day after meals, for 4 consecutive weeks.Abdominal pain, biliary dyspepsia, traditional Chinese medicine (TCM) syndromes, and imaging findings of the biliary system were recorded before and after treatment to evaluate the efficacy of medication, and adverse drug reactions were monitored to evaluate the safety of Danshu Capsule.The Wilcoxon signed-rank test was used for comparison of non-normally distributed continuous data before and after treatment, and the Wilcoxon rank-sum test was used for comparison between any two groups.The paired chi-square test was used for comparison of categorical data before and after treatment; the Kruskal-Wallis H method was used for comparison between multiple groups, and the Logistic regression analysis and the Nemenyi test was used for further comparison between two groups. Results After treatment with Danshu Capsule, all patients had significant reductions in the overall incidence rate of pain induced by lipid meal (χ²=32.422, P < 0.001), the frequency, duration, and degree of pain (Z=-1.985, -2.887, and-3.178, all P < 0.05), the symptom scores of abdominal distension, abdominal fullness, belching, and nausea (all P < 0.001), and the total symptom score of biliary dyspepsia (Z=-4.128, P < 0.001);there were also significant reductions in the TCM syndrome scores of right upper quadrant pain, bitter taste, acid regurgitation, chest distress, abdominal distension, poor appetite, and heaviness of limbs (all P < 0.05) and a significant reduction in total TCM syndrome score (Z=3.860, P < 0.001).Subgroup analysis showed that after treatment, the gallstones group, the chronic cholecystitis group, and the chronic cholecystitis+gallstones group had significant reductions in the degree, frequency, and duration of pain, the symptom score of biliary dyspepsia, and TCM syndrome score (all P < 0.05), as well as a significant reduction in the number of patients with pain induced by lipid meal (P < 0.001).The chronic cholecystitis group had significantly greater reductions in the score of pain frequency, the score of pain duration, the score of pain degree compared with the other two groups (all P < 0.05).Ultrasound examination showed that after treatment, all patients had significant reductions in poor sound transmission of gallbladder, gallbladder wall thickness, incidence rate of gallbladder wall thickening or roughness, and the number and size of gallstones (all P < 0.05).Danshu Capsule showed an overall response rate of 74.75% in the treatment of gallbladder wall lesion and an overall response rate of 67.40% in the treatment of gallstones.A total of 84 patients reported adverse events, mainly gastrointestinal symptoms, and the overall incidence rate of adverse reactions was 0.87%. Conclusion Danshu Capsule can significantly alleviate the symptom of pain and improve the symptoms of biliary dyspepsia, TCM syndrome, and gallbladder imaging findings in patients with chronic cholecystitis and/or gallstones, with a low incidence rate of adverse reactions, and therefore, it is a safe and effective drug for the treatment of chronic cholecystitis and gallstones.
- Cholecystitis,
- Choledocholithiasis,
- Drug Therapy

FullText(HTML)

References(40)

References

[1]	Editorial Board of Chinese Journal of Digestion. Chinese consensus on the medical diagnosis and treatment of chronic cholecystitis and gallstones (2014, Shanghai)[J]. J Clin Hepatol, 2015, 31(1): 7-11. DOI: 10.3969/j.issn.1001-5256.2015.01.002. 中华消化杂志编辑委员会. 中国慢性胆囊炎、胆囊结石内科诊疗共识意见(2014年, 上海)[J]. 临床肝胆病杂志, 2015, 31(1): 7-11. DOI: 10.3969/j.issn.1001-5256.2015.01.002.
[2]	Branch of Gastrointestinal Diseases, China Association of Chinese Medicine. Consensus on diagnosis and treatment of cholecystitis by Chinese medicine (2017)[J]. Chin J Integr Trad West Med, 2017, 25(4): 241-246. DOI: 10.3969/j.issn.1671-038X.2017.04.01. 中华中医药学会脾胃病分会. 胆囊炎中医诊疗专家共识意见(2017)[J]. 中国中西医结合消化杂志, 2017, 25(4): 241-246. DOI: 10.3969/j.issn.1671-038X.2017.04.01.
[3]	YAN GB. Numerical rating scale, NRS[J/CD]. Chin J Joint Surg: Electronic Version, 2014, 8(3): 410. 严广斌. NRS疼痛数字评价量表numerical rating scale[J/CD]. 中华关节外科杂志(电子版), 2014, 8(3): 410.
[4]	ZHANG YG, ZHANG L. 108 cases of cholelithiasis treated with Danshu capsule[J]. Shaanxi J Tradit Chin Med, 2015, 36(5): 531-533. DOI: 10.3969/j.issn.1000-7369.2015.05.007. 张印纲, 张磊. 胆舒胶囊治疗胆石症108例[J]. 陕西中医, 2015, 36(5): 531-533. DOI: 10.3969/j.issn.1000-7369.2015.05.007.
[5]	Branch of Gastrointestinal Diseases, China Association of Chinese Medicine. Consensus on diagnosis and treatment of cholecystitis by Chinese medicine (Hainan 2011)[J]. Chin J Integr Trad West Med, 2012, 32(11): 1461-1465. https://xuewen.cnki.net/CCND-RMRB202204150020.html 中华中医药学会脾胃病分会. 胆囊炎中医诊疗共识意见(2011年, 海南)[J]. 中国中西医结合杂志, 2012, 32(11): 1461-1465. https://xuewen.cnki.net/CCND-RMRB202204150020.html
[6]	Committee on Digestive Diseases, China Society of Integrated Traditional Chinese and Western Medicine. Consensus on the diagnosis and treatment of cholelithiasis by integrative medicine[J]. Chin J Integr Trad West Med, 2011, 31(8): 1041-1043. https://www.cnki.com.cn/Article/CJFDTOTAL-ZXPW201802004.htm 中国中西医结合学会消化系统疾病专业委员会. 胆石症中西医结合诊疗共识[J]. 中国中西医结合杂志, 2011, 31(8): 1041-1043. https://www.cnki.com.cn/Article/CJFDTOTAL-ZXPW201802004.htm
[7]	JIANG SL, LIU P. Current status and perspectives of integrated traditional Chinese and Western medicine therapy for hepatobiliary and pancreatic diseases[J]. J Clin Hepatol, 2020, 36(1): 10-13. DOI: 10.3969/j.issn.1001-5256.2020.01.001. 蒋式骊, 刘平. 肝胆胰疾病中西医结合治疗现状与展望[J]. 临床肝胆病杂志, 2020, 36(1): 10-13. DOI: 10.3969/j.issn.1001-5256.2020.01.001.
[8]	GRIGOLEIT HG, GRIGOLEIT P. Pharmacology and preclinical pharmacokinetics of peppermint oil[J]. Phytomedicine, 2005, 12(8): 612-616. DOI: 10.1016/j.phymed.2004.10.007.
[9]	VO LT, CHAN D, KING RG. Investigation of the effects of peppermint oil and valerian on rat liver and cultured human liver cells[J]. Clin Exp Pharmacol Physiol, 2003, 30(10): 799-804. DOI: 10.1046/j.1440-1681.2003.03912.x.
[10]	ZONG L, QU Y, LUO DX, et al. Preliminary experimental research on the mechanism of liver bile secretion stimulated by peppermint oil[J]. J Dig Dis, 2011, 12(4): 295-301. DOI: 10.1111/j.1751-2980.2011.00513.x.
[11]	HU G, YUAN X, ZHANG S, et al. Research on choleretic effect of menthol, menthone, pluegone, isomenthone, and limonene in DanShu capsule[J]. Int Immunopharmacol, 2015, 24(2): 191-197. DOI: 10.1016/j.intimp.2014.12.001.
[12]	BLACK CJ, YUAN Y, SELINGER CP, et al. Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: A systematic review and network meta-analysis[J]. Lancet Gastroenterol Hepatol, 2020, 5(2): 117-131. DOI: 10.1016/S2468-1253(19)30324-3.
[13]	WEERTS Z, MASCLEE A, WITTEMAN B, et al. Efficacy and safety of peppermint oil in a randomized, double-blind trial of patients with irritable bowel syndrome[J]. Gastroenterology, 2020, 158(1): 123-136. DOI: 10.1053/j.gastro.2019.08.026.
[14]	DAI L, ZHONG LL, JI G. Irritable bowel syndrome and functional constipation management with integrative medicine: A systematic review[J]. World J Clin Cases, 2019, 7(21): 3486-3504. DOI: 10.12998/wjcc.v7.i21.3486.
[15]	HILLS JM, AARONSON PI. The mechanism of action of peppermint oil on gastrointestinal smooth muscle. An analysis using patch clamp electrophysiology and isolated tissue pharmacology in rabbit and guinea pig[J]. Gastroenterology, 1991, 101(1): 55-65. DOI: 10.1016/0016-5085(91)90459-x.
[16]	KRUEGER D, SCHÄUFFELE S, ZELLER F, et al. Peppermint and caraway oils have muscle inhibitory and pro-secretory activity in the human intestine in vitro[J]. Neurogastroenterol Motil, 2020, 32(2): e13748. DOI: 10.1111/nmo.13748.
[17]	PIMENTEL M, BONORRIS GG, CHOW EJ, et al. Peppermint oil improves the manometric findings in diffuse esophageal spasm[J]. J Clin Gastroenterol, 2001, 33(1): 27-31. DOI: 10.1097/00004836-200107000-00007.
[18]	MICKLEFIELD G, JUNG O, GREVING I, et al. Effects of intraduodenal application of peppermint oil (WS(R) 1340) and caraway oil (WS(R) 1520) on gastroduodenal motility in healthy volunteers[J]. Phytother Res, 2003, 17(2): 135-140. DOI: 10.1002/ptr.1089.
[19]	PAPATHANASOPOULOS A, ROTONDO A, JANSSEN P, et al. Effect of acute peppermint oil administration on gastric sensorimotor function and nutrient tolerance in health[J]. Neurogastroenterol Motil, 2013, 25(4): e263-e271. DOI: 10.1111/nmo.12102.
[20]	de SOUSA AA, SOARES PM, de ALMEIDA AN, et al. Antispasmodic effect of Mentha piperita essential oil on tracheal smooth muscle of rats[J]. J Ethnopharmacol, 2010, 130(2): 433-436. DOI: 10.1016/j.jep.2010.05.012.
[21]	TSAI CC, LEE MC, TEY SL, et al. Mechanism of resveratrol-induced relaxation in the human gallbladder[J]. BMC Complement Altern Med, 2017, 17(1): 254. DOI: 10.1186/s12906-017-1752-x.
[22]	GÖBEL H, SCHMIDT G, SOYKA D. Effect of peppermint and eucalyptus oil preparations on neurophysiological and experimental algesimetric headache parameters[J]. Cephalalgia, 1994, 14(3): 228-234; discussion 182. DOI: 10.1046/j.1468-2982.1994.014003228.x.
[23]	FANG Y, ZHU J, DUAN W, et al. Inhibition of muscular nociceptive afferents via the activation of cutaneous nociceptors in a rat model of inflammatory muscle pain[J]. Neurosci Bull, 2020, 36(1): 1-10. DOI: 10.1007/s12264-019-00406-4.
[24]	CEN L, PAN J, ZHOU B, et al. Helicobacter Pylori infection of the gallbladder and the risk of chronic cholecystitis and cholelithiasis: A systematic review and meta-analysis[J]. Helicobacter, 2018, 23(1): e12457. DOI: 10.1111/hel.12457.
[25]	XIE CY, ZHANG P, YANG H, et al. Influencing factors for infection with multidrug-resistant organisms in patients with chronic calculous cholecystitis[J]. J Clin Hepatol, 2020, 36(11): 2489-2493. DOI: 10.3969/j.issn.1001-5256.2020.11.018. 谢朝云, 张萍, 杨怀, 等. 慢性结石性胆囊炎多重耐药菌感染的影响因素分析[J]. 临床肝胆病杂志, 2020, 36(11): 2489-2493. DOI: 10.3969/j.issn.1001-5256.2020.11.018.
[26]	DI CIAULA A, WANG DQ, PORTINCASA P. An update on the pathogenesis of cholesterol gallstone disease[J]. Curr Opin Gastroenterol, 2018, 34(2): 71-80. DOI: 10.1097/MOG.0000000000000423.
[27]	FETISSOV SO. Role of the gut microbiota in host appetite control: Bacterial growth to animal feeding behaviour[J]. Nat Rev Endocrinol, 2017, 13(1): 11-25. DOI: 10.1038/nrendo.2016.150.
[28]	RINGEL-KULKA T, BENSON AK, CARROLL IM, et al. Molecular characterization of the intestinal microbiota in patients with and without abdominal bloating[J]. Am J Physiol Gastrointest Liver Physiol, 2016, 310(6): G417-G426. DOI: 10.1152/ajpgi.00044.2015.
[29]	RIED K, TRAVICA N, DORAIRAJ R, et al. Herbal formula improves upper and lower gastrointestinal symptoms and gut health in Australian adults with digestive disorders[J]. Nutr Res, 2020, 76: 37-51. DOI: 10.1016/j.nutres.2020.02.008.
[30]	MAY B, FUNK P, SCHNEIDER B. Peppermint oil and caraway oil in functional dyspepsia-efficacy unaffected by H. pylori[J]. Aliment Pharmacol Ther, 2003, 17(7): 975-976. DOI: 10.1046/j.1365-2036.2003.01522.x.
[31]	ROSHAN N, RILEY TV, KNIGHT DR, et al. Natural products show diverse mechanisms of action against Clostridium difficile[J]. J Appl Microbiol, 2019, 126(2): 468-479. DOI: 10.1111/jam.14152.
[32]	MOHAMED SH, MOHAMED MSM, KHALIL MS, et al. Combination of essential oil and ciprofloxacin to inhibit/eradicate biofilms in multidrug-resistant Klebsiella pneumoniae[J]. J Appl Microbiol, 2018, 125(1): 84-95. DOI: 10.1111/jam.13755.
[33]	SCHELZ Z, MOLNAR J, HOHMANN J. Antimicrobial and antiplasmid activities of essential oils[J]. Fitoterapia, 2006, 77(4): 279-285. DOI: 10.1016/j.fitote.2006.03.013.
[34]	WACHER VJ, WONG S, WONG HT. Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly (ethylene glycol 1000) succinate (TPGS) and ketoconazole[J]. J Pharm Sci, 2002, 91(1): 77-90. DOI: 10.1002/jps.10008.
[35]	MUNTEAN D, LICKER M, ALEXA E, et al. Evaluation of essential oil obtained from Menthaxpiperita L. against multidrug-resistant strains[J]. Infect Drug Resist, 2019, 13(8): e0200902. DOI: 10.1371/journal.pone.0200902.
[36]	WIŃSKA K, MĄCZKA, ŁYCZKO J, et al. Essential oils as antimicrobial agents-myth or real alternative?[J]. Molecules, 2019, 24(11): 2130. DOI: 10.3390/molecules24112130.
[37]	HEIMES K, HAUK F, VERSPOHL EJ. Mode of action of peppermint oil and (-)-menthol with respect to 5-HT₃ receptor subtypes: Binding studies, cation uptake by receptor channels and contraction of isolated rat ileum[J]. Phytother Res, 2011, 25(5): 702-708. DOI: 10.1002/ptr.3316.
[38]	YIN Y, LEE SY. Current view of ligand and lipid recognition by the menthol receptor TRPM8[J]. Trends Biochem Sci, 2020, 45(9): 806-819. DOI: 10.1016/j.tibs.2020.05.008.
[39]	HOUGHTON JW, CARPENTER G, HANS J, et al. Agonists of orally expressed TRP channels stimulate salivary secretion and modify the salivary proteome[J]. Mol Cell Proteomics, 2020, 19(10): 1664-1676. DOI: 10.1074/mcp.RA120.002174.
[40]	BANOVCIN P, DURICEK M, ZATKO T, et al. The infusion of menthol into the esophagus evokes cold sensations in healthy subjects but induces heartburn in patients with gastroesophageal reflux disease (GERD)[J]. Dis Esophagus, 2019, 32(11): doz038. DOI: 10.1093/dote/doz038.

Relative Articles

[1]	Changxu LI, Xuemin LI, Zhanqiang LIANG, Xibin DUAN, Pengsheng YANG. Application of indocyanine green fluorescence navigation in laparoscopic cholecystectomy after percutaneous transhepatic gallbladder drainage in elderly patients with acute cholecystitis[J]. Journal of Clinical Hepatology, 2023, 39(4): 885-891. doi: 10.3969/j.issn.1001-5256.2023.04.020
[2]	XIE ChaoYun, ZHANG Ping, YANG Huai, MO LiXian, WANG MinKai. Influencing factors for infection with multidrug-resistant organisms in patients with chronic calculous cholecystitis[J]. Journal of Clinical Hepatology, 2020, 36(11): 2489-2493. doi: 10.3969/j.issn.1001-5256.2020.11.018
[3]	He XiangYi, Shi Jian. Consensus on diagnosis and treatment of chronic cholecystitis and gallstones in China (2018)[J]. Journal of Clinical Hepatology, 2019, 35(6): 1231-1236. doi: 10.3969/j.issn.1001-5256.2019.06.011
[4]	Xu JingChang, Ye Hui, Wang DaSong. Research advances in drugs for the prevention and treatment of gallstones[J]. Journal of Clinical Hepatology, 2018, 34(11): 2453-2457. doi: 10.3969/j.issn.1001-5256.2018.11.041
[5]	Du QianCheng, Zhou Ying, Zhang LingQiang, Hu ChenLiang, Fan HaiNing. Individualized treatment of calculous cholecystitis[J]. Journal of Clinical Hepatology, 2018, 34(10): 2251-2256. doi: 10.3969/j.issn.1001-5256.2018.10.042
[6]	Zhang QingKai, Shang Dong. Application of combination of various endoscopic techniques in treatment of bile duct stones[J]. Journal of Clinical Hepatology, 2017, 33(4): 651-655. doi: 10.3969/j.issn.1001-5256.2017.04.010
[7]	Ren CaiYuan, Ren Feng, Li JunFeng, Ding Mei, Chen Yu, Duan ZhongPing, Zhang HuanHu. Clinical effect of Pien Tze Huang in treatment of guinea pigs with cholecystitis induced by lithocholic acid given by gavage[J]. Journal of Clinical Hepatology, 2017, 33(5): 905-908. doi: 10.3969/j.issn.1001-5256.2017.05.023
[8]	Li ZhenLi, Yang Tian. Diagnosis and surgical treatment of xanthogranulomatous cholecystitis[J]. Journal of Clinical Hepatology, 2017, 33(2): 247-252. doi: 10.3969/j.issn.1001-5256.2017.02.007
[9]	Zhang JingZhe, Yu Kui. Integrated traditional Chinese and Western medicine therapy for acute and chronic cholecystitis[J]. Journal of Clinical Hepatology, 2017, 33(5): 838-842. doi: 10.3969/j.issn.1001-5256.2017.05.009
[10]	Liang FaSheng, Lan YunXia, Liang Jie, Ding Jie, Gao XiaoJun. Value of gallbladder-preserving partial cholecystectomy in treatment of abnormal gallbladder morphology complicated by sand-like calculous cholecystitis[J]. Journal of Clinical Hepatology, 2016, 32(10): 1932-1935. doi: 10.3969/j.issn.1001-5256.2016.10.022
[11]	Zhang HaoYu, Liu Bin. Research advances in surgical treatment of intrahepatic bile duct stones[J]. Journal of Clinical Hepatology, 2015, 31(10): 1726-1729. doi: 10.3969/j.issn.1001-5256.2015.10.046
[12]	Wei LuJia. Evaluation of clinical efficacy of different medications for acute biliary colic[J]. Journal of Clinical Hepatology, 2015, 31(10): 1615-1617. doi: 10.3969/j.issn.1001-5256.2015.10.013
[13]	Editorial Board of Chinese Journal of Digestion. Chinese consensus on the medical diagnosis and treatment of chronic cholecystitis and gallstones (2014, Shanghai)[J]. Journal of Clinical Hepatology, 2015, 31(1): 7-11. doi: 10.3969/j.issn.1001-5256.2015.01.002
[14]	Liu Qin, Yang JianBo. Suppurative cholecystitis after two times of esophageal variceal sclerotherapy: a report of one case[J]. Journal of Clinical Hepatology, 2014, 30(7): 679-680. doi: 10.3969/j.issn.1001-5256.2014.07.028
[15]	Kong Jing, Wu ShuoDong. Comprehensive review of strategies for diagnosis and treatment of hepatolithiasis[J]. Journal of Clinical Hepatology, 2013, 29(3): 163-165.
[16]	Cui Long, Xu Zhi, Ling XiaoFeng, Wang LiXin, Hou ChunSheng, Wang Gang, Zhou XiaoSi. A study of minimally invasive treatment for hepatolithiasis[J]. Journal of Clinical Hepatology, 2013, 29(6): 411-413+423.
[17]	Chen Peng, Hu LiHua, Cai Yu, Shi ChunLin, Zhang PeiYi. Outcome of five cases of balloon dilatation to remove common bile duct residual stones via the T-tube tract[J]. Journal of Clinical Hepatology, 2013, 29(3): 230-231.
[19]	Zhang WenJun, Li ZhaoShen, Xie WeiFen, Yuan YaoZong, Li DingGuo, Jiang YiBin, Wu ShuMing. The effect and safety of Ginqiandantong oral liquid on cholecystitis and cholelithiasis[J]. Journal of Clinical Hepatology, 2003, 19(4): 229-231.

Supplements(0)

Cited By

Cited by

Periodical cited type(9)

1.	毛堂友，姚树坤，白宇宁，谢春娥，李晓红，李军祥. 胆石症中西医结合诊疗专家共识(2025年). 中国中西医结合消化杂志. 2025(03): 242-251 .
2.	林依娜，刘璐. 柴胡四金汤配合胆石利通片治疗结石性胆囊炎临床观察. 实用中医药杂志. 2024(02): 233-235 .
3.	梁育川，张达明，杨进波，裴爱华，王晓琴，郭春燕. 胆囊后三角解剖入路腹腔镜胆囊切除术治疗胆囊结石合并慢性胆囊炎患者的临床效果. 大医生. 2024(14): 135-138 .
4.	陈文龙，富裕. 经胆囊后三角解剖入路行腹腔镜胆囊切除术对慢性胆囊炎合并胆结石患者免疫功能及应激反应的影响. 临床医学研究与实践. 2024(24): 78-81 .
5.	薛松，林陈焕. 大柴胡汤加减联合常规药物治疗慢性胆囊炎合并胆道小结石的临床价值. 北方药学. 2024(09): 144-146 .
6.	林惠明，朱璐璐，徐文娟，邓立新，张鸣青. 胆总管结石患者小肠动力障碍和局部微环境变化的研究. 中国医师杂志. 2023(04): 603-606 .
7.	石建敏，邹秋红，邹丹丹. 胆舒胶囊联合腹腔镜微创取石术对胆囊结石患者胆囊收缩功能及炎症反应的影响观察. 现代诊断与治疗. 2023(12): 1760-1762 .
8.	王玥晴，田虎. 中医药防治慢性结石性胆囊炎研究进展. 光明中医. 2023(17): 3348-3351 .
9.	黄灵. 金鸡清热排石丸联合熊去氧胆酸治疗胆石症疗效观察. 实用中医药杂志. 2023(12): 2411-2413 .

Other cited types(8)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(9)

Get Citation

PDF

XML

Article Metrics

Article views (2450) PDF downloads(96)

Clinical efficacy and safety of Danshu Capsule in treatment of chronic cholecystitis and gallstones

DOI: 10.3969/j.issn.1001-5256.2022.09.025